Brokers Set Expectations for Replimune Group Q1 Earnings

Key Points

• Leerink Partners has reduced its Q1 2026 earnings per share estimate for Replimune Group to ($0.77), down from a previous estimate of ($0.70), and currently holds a "Hold" rating on the stock.
• Several brokerages have lowered their ratings for Replimune Group, with Piper Sandler and Barclays both setting target prices of $3.00 for the stock, a decrease from previous estimates.
• In the last 90 days, insiders at Replimune Group have sold a total of 74,907 shares of company stock, reducing their ownership stake to 8.80% of the company.

Replimune Group, Inc. (NASDAQ:REPL - Free Report) - Research analysts at Leerink Partnrs cut their Q1 2026 earnings estimates for shares of Replimune Group in a note issued to investors on Tuesday, July 22nd. Leerink Partnrs analyst J. Chang now expects that the company will earn ($0.77) per share for the quarter, down from their prior estimate of ($0.70). Leerink Partnrs has a "Hold" rating on the stock. The consensus estimate for Replimune Group's current full-year earnings is ($2.97) per share. Leerink Partnrs also issued estimates for Replimune Group's Q2 2026 earnings at ($0.62) EPS, Q3 2026 earnings at ($0.47) EPS, Q4 2026 earnings at ($0.39) EPS, FY2026 earnings at ($2.25) EPS and FY2027 earnings at ($1.24) EPS.

Several other research firms have also recently issued reports on REPL. JPMorgan Chase & Co. reiterated a "neutral" rating and issued a $9.00 target price (down from $19.00) on shares of Replimune Group in a research note on Tuesday, July 22nd. Piper Sandler lowered shares of Replimune Group from an "overweight" rating to a "neutral" rating and set a $3.00 target price on the stock. in a report on Tuesday, July 22nd. HC Wainwright lowered shares of Replimune Group from a "buy" rating to a "neutral" rating in a report on Wednesday, July 23rd. Cantor Fitzgerald lowered shares of Replimune Group from a "strong-buy" rating to a "hold" rating in a report on Tuesday, July 22nd. Finally, Wedbush reissued a "neutral" rating and issued a $4.00 price target (down previously from $19.00) on shares of Replimune Group in a report on Tuesday, July 22nd. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating, two have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, Replimune Group presently has an average rating of "Hold" and a consensus target price of $7.67.

Replimune Group Stock Performance

REPL traded up $0.48 on Friday, hitting $3.65. The company's stock had a trading volume of 16,546,500 shares, compared to its average volume of 2,309,541. The company's 50 day simple moving average is $9.17 and its 200-day simple moving average is $10.17. The firm has a market cap of $281.38 million, a P/E ratio of -1.19 and a beta of 0.61. Replimune Group has a 12 month low of $2.68 and a 12 month high of $17.00. The company has a quick ratio of 7.95, a current ratio of 7.95 and a debt-to-equity ratio of 0.17.

Replimune Group (NASDAQ:REPL - Get Free Report) last released its earnings results on Thursday, May 22nd. The company reported ($0.82) earnings per share for the quarter, missing analysts' consensus estimates of ($0.75) by ($0.07). During the same quarter in the previous year, the company earned ($0.25) EPS.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in the stock. TD Asset Management Inc raised its holdings in shares of Replimune Group by 18.7% during the second quarter. TD Asset Management Inc now owns 327,452 shares of the company's stock valued at $3,042,000 after purchasing an additional 51,600 shares during the last quarter. Goldman Sachs Group Inc. grew its position in Replimune Group by 20.9% during the first quarter. Goldman Sachs Group Inc. now owns 690,167 shares of the company's stock valued at $6,729,000 after buying an additional 119,145 shares during the period. Optimize Financial Inc bought a new stake in Replimune Group during the first quarter valued at approximately $140,000. Exome Asset Management LLC grew its position in Replimune Group by 438.6% during the first quarter. Exome Asset Management LLC now owns 294,846 shares of the company's stock valued at $2,875,000 after buying an additional 240,108 shares during the period. Finally, Dynamic Technology Lab Private Ltd bought a new position in shares of Replimune Group in the first quarter worth approximately $343,000. 92.53% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Replimune Group

In other Replimune Group news, Director Philip Astley-Sparke sold 32,279 shares of Replimune Group stock in a transaction dated Tuesday, May 20th. The shares were sold at an average price of $8.06, for a total value of $260,168.74. Following the completion of the transaction, the director directly owned 1,405,071 shares of the company's stock, valued at approximately $11,324,872.26. The trade was a 2.25% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Konstantinos Xynos sold 7,952 shares of Replimune Group stock in a transaction dated Tuesday, May 20th. The stock was sold at an average price of $8.06, for a total transaction of $64,093.12. Following the completion of the transaction, the insider directly owned 146,933 shares of the company's stock, valued at $1,184,279.98. This trade represents a 5.13% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 74,907 shares of company stock worth $603,655 over the last 90 days. 8.80% of the stock is currently owned by insiders.

About Replimune Group

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.